oxygenase pathways have been identified in mammalian tissue -namely, the 5-, 12-, and 15-lipoxygenases.2A The 5-lipoxygenase pathway metabolises arachidonic acid through two intermediates, 5-hydroperoxyeicosatetranoic acid (5-HPETE) and leukotriene A4 (LTA4), to LTB4 and the sulphidopeptide leukotrienes LTC4, LTD4, and LTE4.5 The sulphidopeptide leukotrienes are potent spasmogens6 for non-vascular smooth muscle and may play a part in the pathogenesis of bronchial asthma. 7`10 The interactions between 5-lipoxygenase and 15-lipoxygenase on arachidonic acid metabolism have recently been studied and a new series of biologically active metabolites described." 12 These molecules have been termed lipoxins. Unlike leukotrienes lipoxins possess a conjugated tetraene structure and the stereochemistries of the two major isomers, lipoxin (LX)A4 and LXB4, are 5S, 6R, 5S-trihydroxy 7,9,13-trans-I 1-cis-eicosatetraenoic acid and 5S, 144R, 1 5S-trihydroxy-6, 10, 12-trans-8-cis-eicosatetraenoic acid, respectively.'314 It is now established that lipoxins can also be generated by an interaction between the 5-and 12-lipoxygenases, when the 12-lipoxygenase acts with a C-15 specificity.
Lipoxins can be generated by human neutrophils, eosinophils, or platelets from both endogenous or exogenous substrates in vitro."' 121516 Furthermore, using gas chromatography and mass spectrometry with selective ion monitoring, LXA4 has been detected in the bronchoalveolar lavage fluid in patients suffering from pulmonary sarcoidosis, infective bronchopneumonia, asthma, and carcinoma ofthe lung.'7 It was not detected in normal subjects. In patients with detectable LXA4 in bronchoalveolar lavage fluid, the ratio of the concentrations of LXA4 to those of sulphidopeptide leukotrienes ranges from 1 9 to 62 (mean , indicating that LXA4 is generated in vivo.
In may act as a partial agonist at the same or similar site as the sulphidopeptide leukotrienes. The fact that 1 5-lipoxygenase is abundant in lung tissue and that LXA4 has been recovered in the bronchoalveolar lavage fluid of patients with asthma and other lung diseases suggests that LXA4 may be a potential mediator or modulator of inflammation in the lung. In a recent study eight subjects underwent inhalation challenge with LXA4,23 but no effect was seen on specific conductance, rate of airflow at 25% vital capacity (V25), blood pressure, pulse, or asthmatic symptoms. There was, however, a significant shift of the specific conductance and V25 dose-response curve to the right after inhalation challenge with LTC4 combined with LXA4 compared with that after inhalation challenge with LTC4 alone. Thus, LXA4 may modulate LTC4-induced airway obstruction in vivo and may act as an endogenous sulphidopeptide leukotriene receptor antagonist.
Further evidence for the anti-inflammatory properties of LXA4 was suggested by the finding that prior exposure of neutrophils or eosinophils to 10 9-106 M LXA4 inhibited the chemotactic responsiveness to LTB4, formyl-methionyl-leucyl-phenylalanine (FMLP), and plasma activating factor in a dose-dependent manner. 24 25 The finding that LXA4 attenuated LTB4-induced neutrophil migration and plasma leakage in the hamster cheek pouch model also supports its putative anti-inflammatory role. 26 There is limited information on the mechanisms for the inhibiting effects of LXA4 on neutrophil functions. The inhibition of chemotactic responses was associated with a concentration-dependent inhibition of phosphoinositide hydrolysis and calcium mobilisation.27 There was no effect on specific binding of [3H] LTB4 to neutrophils following preincubation with LXA4, suggesting that the mechanism of the chemotactic factor-induced phosphoinositide hydrolysis was at a post-receptor level. Structure function studies on the mechanism of inhibition of LXA4 on LTB4-induced neutrophil migration demonstrated the importance of two adjacent free hydroxy groups in either the R or the S configuration; one hydroxy group has to be in a C-6 position, but the other hydroxy group can be in either the C-5 or the C-7 position for conferment of inhibitory activity.21
Successful elucidation of the mechanism(s) for the inhibitory activity of LXA4 may provide a novel therapeutic approach in inflammatory diseases. 
